Silent Pool ‘unimpressed’ by Portman Group code violation ruling
26th February 2021
CBD in the United Kingdom
The UK is one of our tier-1 countries and the biggest market in Europe, making is a very important country to watch. This page includes all of our detailed full-length UK market and regulatory reports, as well as both business and regulatory briefings covering current updates from the country.
Business briefing
Regulatory briefing
No Home Office change in CBD importation licensing requirements
12th February 2021
Market reports
Top brands & pricing report: the UK market, Q4 2020 – overview
16th February 2021
Regulatory reports
Regulatory report: medical and recreational cannabis – a global overview
9th November 2020
Market trackers
UK price & product benchmarking dashboard Q4 2020
15th February 2021
Charts and infographics
UK CBD oil price change index
3rd September 2020
Alerts roundup
CBD-Intel regulatory news in brief, 20-26th February
26th February 2021
UK market continues to expand while is CBD not a scheduled substance
As one of the biggest CBD markets, the UK is an important one and continues to grow in all product categories and across all distribution channels. CBD is not a scheduled product under UK law and its legal status as a finished product is dependent on its intended use.
In 2016, the Medicines and Healthcare Products Regulatory Agency (MHRA) issued a statement saying any CBD-products used as a medicine or advertised as such are to be considered a medicine and therefore require medicinal licensing. CBD products cannot make any medical claims if they are to avoid the need for medical compliance.
It remains to be seen how Brexit will change things for CBD, with the UK Home Office having stated it has no plans to ease restrictions on using flowers for extraction, and confusion continuing over novel food applications.
